Is This Top Dividend in Trouble?
Bristol-Myers Squibb has had anything but a good ride in the wake of the patent cliff. The patent expiration of the company's former top-selling drug, Plavix, has obliterated the drug's sales in 2013 and taken a hammer to Bristol's top and bottom lines. Other top-selling drugs haven't been able to cover up Plavix's holes, but Bristol's stock hasn't suffered so far: Shares in this big pharma leader are up more than 28% year-to-date.
However, Bristol's falling income is making its 3.3% dividend look vulnerable. The company has raised its dividend every year since 2010, but will that continue now that Bristol's staring down the barrel of patent losses and falling revenue?
In the video below, Fool contributor Dan Carroll tells you what you need to know about Bristol's dividend and whether income investors should place their faith in this pharmaceutical giant that's adapting to life with the patent cliff.
Big pharma stocks like Bristol can offer some great dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Is This Top Dividend in Trouble? originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.